[go: up one dir, main page]

PE20110583A1 - Comprimidos de capecitabina de disgregacion rapida - Google Patents

Comprimidos de capecitabina de disgregacion rapida

Info

Publication number
PE20110583A1
PE20110583A1 PE2011001070A PE2011001070A PE20110583A1 PE 20110583 A1 PE20110583 A1 PE 20110583A1 PE 2011001070 A PE2011001070 A PE 2011001070A PE 2011001070 A PE2011001070 A PE 2011001070A PE 20110583 A1 PE20110583 A1 PE 20110583A1
Authority
PE
Peru
Prior art keywords
capecitabin
composition
disgregation
tablets
rapid
Prior art date
Application number
PE2011001070A
Other languages
English (en)
Inventor
Maria Oksana Bachynsky
Mohammad Rashed
Navnit Hargovindas Shah
Paul Anthony Samtak
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41600677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110583(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20110583A1 publication Critical patent/PE20110583A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA RECUBIERTA POR UNA PELICULA, DONDE DICHA COMPOSICION COMPRENDE: a) CAPECITABINA (5'-DESOXI-5-FLUORO-N-[(PENTILOXI)-CARBONIL]-CITIDINA) EN UNA CANTIDAD DE ENTRE 10% A 50% DEL PESO TOTAL DE LA COMPOSICION DEL NUCLEO, b) UNA FORMULACION DISGREGANTE QUE CONSITE EN MANITOL (90%), CROSPOVIDONA (5%) Y ACETATO DE POLIVINILO (5%). TAMBIEN PUEDE EMPLEARSE OTROS DISGREGANTES TALES COMO CROSPOVIDONA DE TAMANO DE PARTICULA INFERIOR A 15 MICRAS, CROSCARMELOSA SODICA, GLICOLATO DE ALMIDON SODICO E HIDROXIPROPILCELULOSA, O UNA COMBINACION DE LAS MISMAS. DICHA COMPOSICION SE PRESENTA BAJO LA FORMA DE UN COMPRIMIDO QUE SE DISGREGA RAPIDAMENTE
PE2011001070A 2008-12-16 2009-12-07 Comprimidos de capecitabina de disgregacion rapida PE20110583A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12276608P 2008-12-16 2008-12-16

Publications (1)

Publication Number Publication Date
PE20110583A1 true PE20110583A1 (es) 2011-08-17

Family

ID=41600677

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001070A PE20110583A1 (es) 2008-12-16 2009-12-07 Comprimidos de capecitabina de disgregacion rapida

Country Status (17)

Country Link
US (1) US20110027374A1 (es)
EP (1) EP2379065A2 (es)
JP (1) JP2012512142A (es)
KR (1) KR20110086857A (es)
CN (1) CN102369002A (es)
AR (1) AR074739A1 (es)
AU (1) AU2009328348A1 (es)
BR (1) BRPI0922983A2 (es)
CA (1) CA2745279A1 (es)
IL (1) IL212735A0 (es)
MX (1) MX2011006026A (es)
PE (1) PE20110583A1 (es)
RU (1) RU2011129205A (es)
SG (1) SG172191A1 (es)
TW (1) TW201028156A (es)
WO (1) WO2010069795A2 (es)
ZA (1) ZA201103986B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8715729B2 (en) 2010-12-22 2014-05-06 Basf Se Rapidly disintegrating, solid coated dosage form
JP6521564B2 (ja) 2010-12-22 2019-05-29 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 速崩性の固体被覆剤形
CN102266303A (zh) * 2011-07-07 2011-12-07 程雪翔 一种卡培他滨药用组合物及其制备方法
US20140309183A1 (en) * 2011-08-24 2014-10-16 David Kerr Low-Dose Combination Chemotherapy
CN102988320B (zh) * 2012-12-13 2014-04-16 哈药集团技术中心 一种卡培他滨分散片及其制备方法
CN104337783B (zh) * 2013-08-02 2018-06-22 山东新时代药业有限公司 一种卡培他滨片剂及其制备方法
CN104997744B (zh) * 2015-08-04 2018-01-23 青岛市中心医院 一种高稳定性卡培他滨片剂及其制备方法
JP6673798B2 (ja) * 2016-10-12 2020-03-25 日本化薬株式会社 カペシタビンを有効成分とするフィルムコート医薬製剤
JP6866113B2 (ja) * 2016-11-01 2021-04-28 日本化薬株式会社 カペシタビンを有効成分とする医薬製剤
JP6792418B2 (ja) * 2016-11-08 2020-11-25 日本化薬株式会社 カペシタビンを有効成分とする医薬製剤の製造方法
PL3720424T3 (pl) * 2017-12-08 2022-12-27 F. Hoffmann-La Roche Ag Preparat farmaceutyczny
WO2021033144A1 (en) * 2019-08-20 2021-02-25 Intas Pharmaceuticals Ltd. Oral suspension of capecitabine
MX2022014094A (es) * 2020-05-19 2022-12-08 Cellix Bio Private Ltd Formulaciones farmaceuticas y sus preparaciones para el tratamiento del cancer.
CN115666516A (zh) * 2020-06-01 2023-01-31 希尔帕医疗保健有限公司 包括卡培他滨的快速分散药物组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8628359D0 (en) * 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
CA2440361A1 (en) * 2001-03-06 2002-09-12 Kyowa Hakko Kogyo Co. Ltd. Intraorally rapidly disintegrable preparation
US7118765B2 (en) * 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
PT1634586E (pt) * 2004-09-09 2007-04-30 Medinfar Produtos Farmaceutico Comprimidos de domperidona rapidamente dispersíveis em água.
JP5209876B2 (ja) * 2004-12-28 2013-06-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 速崩壊性錠剤及びその製造方法
WO2006110800A1 (en) * 2005-04-12 2006-10-19 Elan Pharma International Limited Modified release compositions comprising a fluorocytidine derivative for the treatment of cancer
EP1965761B1 (de) * 2005-12-21 2015-07-01 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
CA2665343C (en) * 2006-10-05 2014-12-16 The Johns Hopkins University Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets

Also Published As

Publication number Publication date
EP2379065A2 (en) 2011-10-26
TW201028156A (en) 2010-08-01
RU2011129205A (ru) 2013-01-27
MX2011006026A (es) 2011-06-21
WO2010069795A3 (en) 2010-10-07
ZA201103986B (en) 2012-02-29
AR074739A1 (es) 2011-02-09
IL212735A0 (en) 2011-07-31
KR20110086857A (ko) 2011-08-01
WO2010069795A2 (en) 2010-06-24
CA2745279A1 (en) 2010-06-24
AU2009328348A1 (en) 2010-06-24
CN102369002A (zh) 2012-03-07
US20110027374A1 (en) 2011-02-03
SG172191A1 (en) 2011-07-28
BRPI0922983A2 (pt) 2016-01-26
JP2012512142A (ja) 2012-05-31

Similar Documents

Publication Publication Date Title
PE20110583A1 (es) Comprimidos de capecitabina de disgregacion rapida
AR067077A1 (es) Preparado solido farmaceutico y metodo de produccion del mismo
AR086249A1 (es) Composiciones de tabletas de disolucion rapida de administracion vaginal
CO6300931A2 (es) Composiciones farmaceuticas que comprenden particulas de liberacion controlada con un nucleo que comprende farmacos levemente basicos
BRPI0913379C1 (pt) intermediário compactado compreendendo dimaleato de bibw 2992, na forma de um pó, e seu método de produção, mistura intermediária ou final, e formulações orais sólidas prontas para o uso/ingestão
ECSP14013168A (es) Tableta a prueba de manipulación que proporciona liberación de fármaco inmediato
MX376094B (es) Composición de medicina china tradicional, y preparación y aplicación de la misma.
JP2013056901A5 (es)
CU24619B1 (es) Letermovir amorfo y formulaciones farmacéuticas sólidas del mismo para administración por via oral
PE20091620A1 (es) Preparacion solida de desintegracion oral
BR112015021403A2 (pt) cápsulas e comprimidos sólidos de benzonatato de liberação modificada
PE20141115A1 (es) Comprimido de desintegracion oral
JP2010132654A5 (es)
PE20110943A1 (es) Formulacion oral solida de alisquireno
IN2015DN02907A (es)
PE20150607A1 (es) Composicion farmaceutica que comprende fimasartan e hidroclorotiazida
CR10668A (es) Comprimidos pediatricos de capecitabina
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative
CR20150297A (es) Producto de comicronización que comprende acetato de ulipristal
JP2015129124A5 (es)
AR088844A1 (es) Formulacion de liberacion inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida
AR080256A1 (es) Formulaciones farmaceuticas solidas de ramipril y besilato de amlodipino y su preparacion
MY169160A (en) Method for producing starch granules, and orally disintegrating tablet
JP2015129175A5 (es)
JP2015534970A5 (es)

Legal Events

Date Code Title Description
FC Refusal